

1 **TITLE:** Protocol for a prospective feasibility study investigating phenoconversion of  
2 *CYP3A4*, *CYP2C19* and *CYP2D6* genotypes in paediatric and adolescent and young adult  
3 patients with an acute diagnosis of Hodgkin or Non-Hodgkin Lymphoma [PEGASUS]  
4 Rachel Conyers<sup>1,2,3</sup>, Tayla Stenta<sup>1</sup>, Ben Felmingham<sup>1</sup>, Andrew Somogyi<sup>4</sup>, Carl Kirkpatrick<sup>5</sup>,  
5 Andreas Halman<sup>1</sup>, Claire Moore<sup>1,2</sup>, Dhrita Khatri<sup>1</sup>, Elizabeth Williams<sup>1</sup>, Roxanne Dyas<sup>1</sup>,  
6 David A. Elliott<sup>1,2,6</sup>, Amanda Gwee<sup>2,7,8</sup>, Marliese Alexander<sup>9,10</sup>

7

8 1. Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Australia.

9 2. Department of Paediatrics, The University of Melbourne, Parkville, Australia.

10 3. Children's Cancer Centre, The Royal Children's Hospital, Parkville, Australia.

11 4. School of Biomedicine, University of Adelaide, Adelaide, Australia

12 5. Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville,  
13 Australia.

14 6. The Novo Nordisk Foundation Centre for Stem Cell Medicine, ReNEW, Melbourne Node,  
15 Parkville, Australia.

16 7. Infectious Disease Department, The Royal Children's Hospital, Parkville, Australia

17 8. Antimicrobials Group, Murdoch Children's Research Institute, Parkville, Australia.

18 9. Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Victoria,  
19 Australia.

20 10. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville,  
21 Victoria, Australia.

22

23 Corresponding Author

24 A/Prof Rachel Conyers

25 Cancer Therapies Group

26 Stem Cell Medicine

27 Murdoch Children's Research Institute

28 Email: [rachel.conyers@mcri.edu.au](mailto:rachel.conyers@mcri.edu.au)

29 Phone: 03 9345 5502

30

31 **KEY WORDS:**

32 Pharmacogenomics, Oncology, Australia, Phenoconversion, pharmacogenomic  
33 implementation.

34 **SHORT RUNNING TITLE:**

35 PEGASUS Protocol: A prospective feasibility study investigating phenoconversion of  
36 *CYP3A4*, *CYP2C19* and *CYP2D6* genotypes in paediatric lymphoma.

37

38 **WORD COUNT:** 8942

39

40 **ABSTRACT (WORDS: 246)**

41

42 **Introduction:** Phenoconversion is the discrepancy between the predicted phenotype based on  
43 genotyping (genotype-based phenotype) and the actual phenotype influenced by non-genetic  
44 factors (clinical phenotype). Despite its potential impact on drug selection, efficacy, toxicity,  
45 and cancer treatment outcomes, research in this area is limited. This study aimed to assess the  
46 acceptability and feasibility of investigating phenoconversion using probe medications in a  
47 paediatric and adolescent and young adult oncology patient population.

48 **Methods and Analysis:** This prospective, single-arm, partially blinded, non-randomized  
49 feasibility study will enrol individuals aged 6-25 with a new diagnosis of Hodgkin  
50 Lymphoma or Non-Hodgkin Lymphoma. Genotyping will be performed at baseline using  
51 whole genome sequencing or targeted panel testing. Longitudinal phenotyping will be  
52 conducted throughout the cancer treatment journey using exogenous oral enzyme-specific  
53 probes, specifically subtherapeutic doses of dextromethorphan (*CYP2D6*) and omeprazole  
54 (*CYP2C19*, *CYP3A4*) for enzyme activity assessment. The primary outcome measure will be  
55 the proportion of patients who consent to the study and successfully complete baseline and at  
56 least two longitudinal time points with valid probe drug metabolic ratio measurements.  
57 Secondary outcomes include classification of clinical phenotypes based on probe drug  
58 metabolic ratios, probe drug safety, barriers to consent, acceptability of pharmacogenomic  
59 and phenoconversion testing, longitudinal genotype/phenotype concordance and  
60 inflammatory profiles, and investigation of patient and disease factors influencing  
61 phenoconversion.

62 **Ethics and Dissemination:** The ethics approval of the trial has been obtained from the  
63 Sydney Childrens Ethics Committee (2023/ETH1954). Findings will be disseminated through  
64 peer-reviewed publications and professional conference presentations.

65 **Trial Registration:** ClinicalTrials.gov NCT 06383338

66

## 67 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 68 • Pioneering study: This is the first study to conduct longitudinal phenotype  
69 assessments in a paediatric and adolescent and young adult oncology population.
- 70 • Primary outcome focus: The primary outcome includes patient consent and successful  
71 longitudinal probe drug derived clinical-phenotype assessments, crucial for designing  
72 future clinical trials.
- 73 • Generalisability: Conducting the study within both paediatric and adult hospital  
74 systems will enhance generalisability.
- 75 • Blinding: Probe drug metabolic ratio assessments are conducted blinded to genotype.
- 76 • Power: The trial is not powered to assess outcomes of or factors influencing  
77 phenoconversion, however secondary outcome evaluations may help prioritise  
78 outcomes/factors for further investigation.

## 79 1. INTRODUCTION

### 80 1.1 BACKGROUND AND RATIONALE

81

82 Genetic polymorphisms have been identified for several cytochromes P450 (CYP450) where  
83 their activity falls into two clearly defined populations; individuals whose rate and extent of  
84 metabolism results in poor metaboliser (PM) status and those who have faster metabolism  
85 resulting in extensive metaboliser (EM) status(1). Examples of these enzymes include  
86 CYP3A4, CYP2C19 and CYP2D6, which metabolise clinically important drugs used in acute  
87 lymphoblastic leukaemia and non-Hodgkin lymphoma therapy and supportive care. This  
88 includes drugs such as cyclophosphamide, bortezomib and omeprazole (CYP2C19); tramadol  
89 and ondansetron (CYP2D6)(2). Identifying these polymorphisms allows prediction of the  
90 clinical phenotype for drug metabolism for patients, thus presenting an opportunity to  
91 personalise patient treatment, with the ultimate goal of maximising treatment efficacy and  
92 minimising toxicity.

93

94 An individual's variability in pharmacokinetics can be secondary to genotype, ontogeny,  
95 gender, comorbidities, inflammation and drug-drug interactions. Ontogeny is of particular  
96 importance in paediatrics whereby paediatric patients can have rapid physiological, maturate  
97 and developmental changes that alter drug metabolism and response. Most recently, there is  
98 growing recognition that there are circumstances in which there is discordance between  
99 predicted phenotype by genotyping, and actual phenotype under the influence of the  
100 aforementioned certain non-genetic factors. This mismatch has been termed  
101 'phenoconversion'. In this era of precision medicine where there is increasing uptake of  
102 pharmacogenomic testing, it is essential to investigate this genotype-phenotype discordance,  
103 as it may have a considerable impact on both cancer-directed and supportive care drug  
104 selection, drug efficacy and toxicity, and potentially cancer treatment outcomes for patients.

105

#### 106 **Phenoconversion studies in adult patients**

107 Adult studies of non-cancer cohorts (n=27 studies), have reported that changes in the activity  
108 of CYP3A4, CYP2C19 and CYP2D6 can occur due to environmental factors, drug  
109 interactions, disease burden and inflammatory state(3). Studies of phenoconversion among  
110 patients with cancer are limited to small retrospective studies of adults with an investigatory  
111 focus on CYP2C19, but these studies have shown to report a discordance between genotype

112 and phenotype (from genotype normal metaboliser to poor metaboliser measured by  
113 phenotype in 29% of patients ) as well as differences in enzyme metabolic activity relative to  
114 non-cancer controls(1, 2). In addition, clinical scenarios that increase inflammation can result  
115 in the up-regulation of interleukin-6 (IL-6). Up-regulation of IL-6 has been shown to reduce  
116 the activity of CYP450 enzymes an exemplar of phenoconversion(3).  
117

## 118 **Phenoconversion studies in paediatrics**

119 Defining CYP activity and its impact on drug response in children is challenging, particularly  
120 hampered by the difficulty in enrolling patients on prospective trials(4). Perhaps best  
121 described in the adult literature is the use of the ‘Geneva cocktail’(5) to study the phenotype  
122 across a range of CYP enzymes and transporters. This group recently published a study  
123 describing the use of CYP phenotyping and/or genotyping tests in 52 paediatric patients.  
124 Phenotyping was performed using exogenous oral enzyme specific probes, namely,  
125 subtherapeutic doses of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan,  
126 midazolam and fexofenadine for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6,  
127 CYP3A4/5 and P-glycoprotein activity. The study was a subpart of three total studies in  
128 adults and children(6-8). It was a retrospective study reviewing the results of patients in in-  
129 patients and out-patient settings (0-17 years) who had CYP genotyping or phenotyping  
130 performed between January 2005 and December 2020 as part of their routine care. Patients  
131 were included if phenotyping was examined using probe medications either as part of the  
132 Geneva cocktail or by administering a specific targeted probe (selective phenotyping (i.e.,  
133 midazolam for testing CYP3A4 enzyme activity). Phenotype determination was based on the  
134 metabolite to parent drug metabolic ratio (MR) measured on capillary or venous samples(8).  
135

## 136 **Indications for Phenotype-Genotype Examination**

137 Investigations of genotype and phenotype were most often carried out because of (i)  
138 insufficient response to treatment; (ii) low plasma concentration; or (iii) an adverse drug  
139 reaction. The majority of prescribed medications for which phenotype/genotype examination  
140 was sought were for immunosuppressants, antipsychotics, analgesics, antiepileptics,  
141 antithrombotics and antifungals(8).  
142  
143

144 **Phenotype-Genotype Concordance Rates**

145 In this combined retrospective study, 52 patients (mean age 9.7 (+/- 5.4 years, range 1 month-  
146 17 years) underwent genotype or phenotype testing over a period of 2 decades. Of the 52  
147 patients, 42% underwent simultaneous genotyping and phenotyping, 23% underwent  
148 phenotyping only and 35% underwent genotyping only. In total 17 patients were able to be  
149 analysed for combined genotype and genotype (mean age 9.3 +/- 5.4 years). The concordance  
150 rates between phenotype and genotype were highly variable ranging from 80% for CYP2C9  
151 to 33% for CYP3A5. Interestingly, in ~50% of the non-concordant groups, the  
152 phenoconversion could be explained by a drug-gene interaction (drug-induced  
153 phenoconversion). Furthermore, in all the CYP2D6 examined patients, the phenotype  
154 exhibited increased activity in comparison to the genotype, raising the question of other  
155 potential causes. The results of the study showed that the patients genotype:phenotype  
156 mismatch explained the clinical reason for phenotype testing (i.e., low therapeutic drug  
157 monitoring levels) in 60% of cases.

158

159 **Probe Drug Administration and Reported Adverse Events**

160 Most patients within the above study received targeted phenotyping (rather than the full  
161 Geneva cocktail) focusing on up to 3 CYP enzymes. Twelve patients received the full  
162 Geneva cocktail. The most frequently examined enzymes were CYP3A4 (n=27) followed by  
163 CYP2D6 (n=23). Of note, no adverse events were reported following targeted or Geneva  
164 Cocktail administration(8).

165

166 **Rationale for the study of phenoconversion in paediatrics and paediatric oncology**The  
167 paediatric population is of particular relevance for phenoconversion in the paediatric  
168 oncology setting with ontogeny, drug-drug interactions and the potential for inflammatory  
169 events either secondary to disease or infection. Furthermore, there is wide inter-individual  
170 variability. These factors combined make safe but also effective drug cancer and supportive  
171 care medication delivery particularly challenging. At any point in time during cancer therapy,  
172 the milieu of factors could lead to increased clearance of a medication and inefficacy, or  
173 conversely, decreased clearance and drug toxicity. Determining and characterising their  
174 influences on drug metabolising enzyme activity to guide therapy is of particular importance  
175 in the era of personalised medicine. This is particularly relevant in paediatric oncology where  
176 (i) there are some high-risk diseases with unexplained poor response to molecular- or chemo-

177 therapy and (ii) where survivorship and long-term therapy related toxicities is of particular  
178 concern.

179

### 180 **Rationale for the study of CYP3A4, CYP2C19 and CYP2D6 enzymes**

181 The decision to assess CYP3A4, CYP2C19 and CYP2D6 enzymes was based both on critical  
182 roles in the metabolism of many oncology and supportive care medicines(9, 10) and the  
183 availability of accessible, safe, and easily prepared, administered, and measured probe  
184 drugs(11)

185

### 186 **Rationale for inclusion of microsampling**

187 Longitudinal phenotype assessments will be conducted using traditional blood draw methods  
188 (central venous access device or peripheral blood) and Volumetric Absorptive Microsampling  
189 (VAMS). The inclusion of VAMS aims to demonstrate its potential for patient self-testing,  
190 thereby minimizing the need for invasive testing and reducing required hospital/pathology  
191 visits. This approach is intended to improve the acceptability of future clinical trials from the  
192 patient perspective, by offering a less burdensome and more convenient option for ongoing  
193 phenotype monitoring. VAMS was selected over traditional dried blood spot (DBS)  
194 microsampling for collection of fixed blood volumes and superior accuracy and  
195 reliability(12).

196

## 197 **1.2 OBJECTIVES**

### 198 **1.2.1 Hypothesis**

199 Probe medications can be administered to measure phenoconversion at multiple timepoints  
200 in the cancer journey in a paediatric/AYA patient population.

201

### 202 **1.2.2 Primary Objective**

203 To test acceptability and feasibility to further studies of phenoconversion using probe  
204 medications in a paediatric/AYA oncology patient population.

205

### 206 **1.2.3 Secondary Objective**

207 1) Classify CYP phenotypes according to metabolic ratio (MR) of probe drug  
208 administration.

- 209 2) To understand barriers to consent and acceptability of the study, from patient and  
210 clinician perspectives.
- 211 3) To understand barriers to viable sample collection, shipping, processing, and timely  
212 reporting.
- 213 4) To understand safety of phenoconversion testing using probe drug administration.
- 214 5) Describe phenoconversion in terms of genotype and phenotype mismatch across  
215 longitudinal timepoints.

216

## 217 **2.0 TRIAL DESIGN**

### 218 **METHODS: PARTICIPANTS, INTERVENTIONS, OUTCOMES**

219

220 **2.1 Trial Design:** Prospective single arm partially blinded and non-randomised feasibility  
221 study.

222

223 The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-  
224 Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer directed and  
225 supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways, are  
226 commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult  
227 cancers. The acceptability and feasibility of this study will inform future studies in  
228 phenoconversion within the cancer population to direct more personalised precision  
229 medicine.

230

### 231 **2.2 Sponsorship, Trial Registration and Version**

232

233 The trial is sponsored by the Murdoch Children's Research Institute and registered with  
234 clinicaltrials.gov NCT 0638338 [first registered 21.03.2024]. It is approved Sydney Childrens  
235 Ethics Committee (2023/ETH1954). The study is currently version 2 26.04.2024.

236

## 237 **3.0 STUDY SETTING**

238

239 PEGASUS will be conducted at two tertiary institute in Victoria, Australia. The study is  
240 focussed on enrolling patients within oncology units within a paediatric unit [The Royal  
241 Children's Hospital, Melbourne] and an adult unit [Peter MacCallum Cancer Institute].

242



## 243 **4.0 ELIGIBILITY CRITERIA**

### 244 **4.1 Participants inclusion criteria**

- 245     ▪ Age 6-25 years of age.
- 246     ▪ New diagnosis of Hodgkin Lymphoma or Non-Hodgkin Lymphoma.
- 247     ▪ Able to swallow and absorb oral or nasogastric tube (NGT) administration of probe
- 248         drugs.
- 249     ▪ Able to provide written informed consent.

250

### 251 **4.2 Participants exclusion criteria**

- 252     ▪ Failure to comply with inclusion criteria.
- 253     ▪ Has a known previous allergy to any of the probe medications (i.e., omeprazole or
- 254         dextromethorphan).
- 255     ▪ Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade IV
- 256         end organ dysfunction (i.e., hepatic, renal, gastrointestinal).
- 257     ▪ Had previous oncological treatment (not first cancer diagnosis).
- 258     ▪ Is a clinically unstable patient requiring intensive care admission in high-risk
- 259         circumstances will not be considered eligible for consent.
- 260     ▪ Any patient requiring urgent initiation of anti-cancer treatment outside hours where a
- 261         member of the study staff is unable to approach the parent/guardian or participant for
- 262         consent prior to commencing anti-cancer therapy will be ineligible for consent.
- 263     ▪ Unable to provide written informed consent.

264

## 265 **5.0 INTERVENTIONS**

266

### 267 **5.1 Treatment arms**

268 This is a single arm study where all participants will undergo genotyping of their CYP3A4,  
269 CYP2C19 and CYP2D6 enzymes either via whole genome sequencing or targeted panel  
270 testing. All participants are given the intervention (two sub-therapeutic probe drugs) with  
271 subsequent blood sampling (2 hours later) to test enzyme activity (phenotyping).

272

273 PEGASUS timepoints are as follows:

- 274     **(i)** Prior to commencing first lymphoma chemotherapy cycle
- 275     **(ii)** 2 months (week 8)
- 276     **(iii)** 4 months (week 16)

277 (iv) Completion of therapy (> week 16)

278 (v) Up to a maximum of 2 febrile neutropenic episodes.

279 A minimum of 24 hours must occur between study visits.

280

281 **6.0 OUTCOMES**

282 Objective and outcome measures are detailed in Table 1.

283

OBJECTIVE	OUTCOME & OUTCOME MEASURE
<b>Primary</b>	
To test acceptability and feasibility of further studies in phenoconversion using probe medications in a paediatric/AYA oncology patient population.	To determine the proportion of patients who consent to study and complete baseline and at least two longitudinal timepoints with successful measurement of probe drug MR.
<b>Secondary</b>	
To classify CYP phenotypes according to MR of probe drug administration.	<ol style="list-style-type: none"> <li>1. Proportion of patients completing all longitudinal blood sampling.</li> <li>2. Proportion of patients with successful detection of probe drug overall and at each sampling timepoint.</li> <li>3. Proportion of patients where phenotype can be classified according to MR overall at each sampling timepoint.</li> <li>4. Proportion of patients using VAMS technique where phenotype can be classified according to MR overall and at each sampling timepoint in comparison to blood draw.</li> </ol>
To apply the TFA to understand barriers to consent and acceptability of participating in pharmacogenomic and phenoconversion testing from patient and clinician perspectives	<ol style="list-style-type: none"> <li>1. Reported acceptability of the study measured via survey at study completion from patient, clinician and clinical trial coordinator perspective.</li> <li>2. Proportion of patients declining consent</li> </ol>

OBJECTIVE	OUTCOME & OUTCOME MEASURE
	<p>and classification of these according to pre-defined parameters at time of consent.</p> <p><b>3.</b> Determine the proportion of patients declining consent or withdrawing consent and classification of these according to pre-defined parameters at time of consent.</p>
To understand safety of phenoconversion testing using probe drug administration.	Percentage of patients experiencing an AE during probe drug administration.
To describe phenoconversion in terms of genotype and phenotype mismatch across longitudinal timepoints.	Incidence of genotype and phenotype mismatch overall across longitudinal timepoints.
To document patient and disease factors that may influence phenoconversion.	<p>Proportion of patients with documentation of all parameters:</p> <ul style="list-style-type: none"> <li>(i) Disease staging and biomarkers of extent of disease (ESR, LDH).</li> <li>(ii) Systemic inflammatory state (CRP, procalcitonin and cytokine panel).</li> <li>(iii) Current medications involving the CYP P450 pathway.</li> <li>(iv) Demographics (age, gender, ethnic background).</li> <li>(v) Other environmental factors (alcohol, smoking, vitamin D status).</li> </ul>
To describe the longitudinal inflammatory profile of patients with Hodgkin or non-Hodgkin Lymphoma.	Inflammatory profile measured by CRP, PCT and cytokine panel.

284 **Table 1:** Trial Objectives and Outcomes. Abbreviations: AE: Adverse Event; AYA:  
 285 Adolescent and young adult; CRP: Cytokine Reactive Protein; ESR: Erythrocyte  
 286 Sedimentation Rate; LDH: Lactate Dehydrogenase; MR: Metabolic ratio; PCT:  
 287 Procalcitonin; TFA: Theoretical Framework of Acceptability; VAMS: Volumetric absorptive  
 288 microsampling;

289 **6.3 Methodology for Primary Outcome Phenotyping**

### 290 **6.3.1 Using Probe Medications for Phenotyping**

291 Phenotyping will be performed using exogenous oral enzyme-specific probes; namely  
292 subtherapeutic doses of dextromethorphan (CYP2D6), omeprazole (CYP2C19) (CYP3A4)  
293 for enzyme activity assessment.

294

295 Several phenotype cocktails have been developed using probe drugs to study human CYP  
296 P450 enzymes. One well known cocktail that has been used is known as the Genevea cocktail  
297 consisting of caffeine, bupropion, flurbiprofen, dextromethorphan, midazolam, omeprazole,  
298 and fexofenadine). The dose of omeprazole and dextromethorphan used in this study was 10  
299 mg of each drug (below the daily therapeutic dose).

300

### 301 **6.3.1 Omeprazole**

302 A proton pump inhibitor with therapeutic effect achieved by binding to the  
303 hydrogen/potassium ATPase enzyme system (proton pump), inhibiting both stimulated and  
304 basal acid secretion. It has several indications and is often used to treat peptic ulcer disease,  
305 gastroesophageal reflux disease, and routinely in oncology patients for the prevention and  
306 treatment of upper gastrointestinal adverse events. Proton pump inhibitors are generally well  
307 tolerated. Further information is available in Supplemental File 1.

308

### 309 **6.3.2 Potential omeprazole adverse effects**

<b>Common (&gt; 1%)</b>	<b>Infrequent (0.1 – 1%)</b>	<b>Rare (&lt; 0.1%)</b>
headache, nausea, vomiting, diarrhoea, abdominal pain, constipation, flatulence.	rash, itch, dizziness, fatigue, drowsiness, insomnia, dry mouth.	gynaecomastia, myalgia/arthralgia, acute interstitial nephritis, peripheral oedema, hepatitis, jaundice, thrombocytopenia, leucopenia, hypersensitivity reactions (i.e., anaphylaxis, Stevens-Johnson syndrome), subacute cutaneous lupus

		erythematosus (very rare).
--	--	----------------------------

310 **Table 2:** Potential adverse effects according to the Australian Medicines Handbook, July  
 311 2023

### 312 6.3.3 Dextromethorphan

313 An opioid derivative (but lacking any opioid activity) dextromethorphan is known to be an *N*-  
 314 methyl-d-aspartate (NMDA) receptor antagonist. However, dextromethorphan binding sites  
 315 are not limited to the known distribution of NMDA receptors. Dextromethorphan also  
 316 inhibits the reuptake of serotonin. The use of dextromethorphan is not recommended by the  
 317 Australian Medical Association for use in children under 6 years of age. Further information  
 318 is available in Supplemental File 2.

### 319 6.3.4 Potential dextromethorphan adverse effects

Common (> 1%)	Infrequent (< 0.1%)	Rare
drowsiness, constipation, nausea, vomiting.	respiratory depression.	This box is intentionally blank.

320 **Table 3:** Potential adverse effects according to the Australian Medicines Handbook, July  
 321 2023

### 322 6.4 Dosage and route of administration

323 Probe drugs will be administered orally or via nasogastric tube. Both probe drugs will be  
 324 administered at the same time, one drug after the other, any order. All patients will receive  
 325 the probe drug dose which is below the safest sub-therapeutic dose for the lowest age range  
 326 (6-year-old). To ensure the safest subtherapeutic dose is administered to individuals that are  
 327 not routinely taking a dose of the probe drug, a dose of 5 mg omeprazole and 5mg  
 328 dextromethorphan will be administered to all participants (Table 4). This is half the dose used  
 329 in the Geneva cocktail where MR have been successfully measured, and the dose has been  
 330 safe and well tolerated with low incidence of adverse events from a single oral dose.

331

	<b>PEGASUS subtherapeutic dosing</b>	<b>Australian Medical Handbook omeprazole</b>	<b>Standard therapeutic dose based on 21kg</b>
--	--	---	--

		<b>therapeutic dosing</b>	
Omeprazole	5mg once (10mg tablet dispersed in 10mL water/juice with 5mL administered).	Birth(at term) (0.7 mg – 1.4 mg/kg DAILY) *  All patients 5 mg daily to 20 mg TWICE daily.	10mg – 20mg once daily
Dextromethorphan	5mg once (2.5mL liquid).	6 yrs to adult * 5mL – 20mL DAILY <u><i>Concentrations may vary if BISOLVON<sup>®</sup> brand is not used.</i></u>	5mL up to FOUR times daily.

332 \* The average weight of a 6-year-old patient according to the Australian Medical Handbook  
333 is 21kg.

334 **Table 4: Probe Drug dosing and administration**

335

336 Probe drugs will be dispensed by site designated pharmacy departments in accordance with  
337 local pharmacy standard operating procedures (SOPs) for dispensing of study medication.  
338 Omeprazole can be dispensed as any commercially available form as approved for use in  
339 Australia by the Therapeutic Goods Administration throughout the study trial. Individual  
340 doses should be dispensed in an amber glass bottle. Dextromethorphan hydrobromide should  
341 be administered using the BISOLVON<sup>®</sup> product as this is the only single agent  
342 commercially available product in Australia approved by the Therapeutic Goods  
343 Administration. If this specific brand is unable to be obtained by the pharmacy department a  
344 suitable combination product must be approved by the study PI. Individual doses should be  
345 dispensed in a single oral syringe for administration.

346

347

348 **6.4.1 Cases where a participant is already taking a probe drug routinely**

349 Omeprazole is often given as a regular medication for patients receiving chemotherapy,  
350 particularly those taking steroid medication (i.e., prednisolone, dexamethasone). In instances  
351 where a patient is already taking a probe medication at therapeutic doses (most likely  
352 omeprazole rather than dextromethorphan) there will be no need to administer a second sub-  
353 therapeutic drug probe dose. The enzyme activity can be measured regardless of the  
354 administered dose using the MR approach. The different dosing regime will be recorded in  
355 study case report forms.  
356

#### 357 **6.4.2 Minimum documentation of medication information by pharmacy**

358 For each probe drug the brand name, batch and expiry must be recorded by the dispensing  
359 pharmacy site for study reference if required. This information should be documented as part  
360 of good routine medication dispensation. All dispensing of medication supply will be verified  
361 by a second staff member. The probe drugs will be dispensed in accordance with the  
362 investigator's prescription. Pharmacy will be responsible for notifying the study PI if there  
363 are any concerns or issues relating to the safe handling and storage of the studies probe drugs  
364 (i.e., temperature excursions, damaged packaging).  
365

#### 366 **6.5 Drug Levels**

##### 367 **6.5.1 Measuring activity of CYP2C19 and CYP3A4 by measuring the MR of omeprazole**

368 The MR of 3 CYPS (3A4, 2C19, 2D6) will be measured 2 hours (+/-30 minutes) following  
369 probe drug administration. MR will be measured by blood draw from CVAD or peripheral  
370 blood draw and VAMS. Blood draw will be taken in a standard EDTA tube and both VAMS  
371 and EDTA will be stored at room temperature until ready for processing.

372 CYP2C19 metabolises R-omeprazole to the hydroxy metabolism which represents almost  
373 90% of R-omeprazole metabolism. CYP2C19 metabolises S-omeprazole to the 5-O-  
374 desmethylmetabolite representing 40% of overall S-omeprazole metabolism.

375

376 CYP3A4 metabolises S-omeprazole to the sulphone metabolite representing ~ 57% of overall  
377 S-omeprazole metabolism. Therefore, administration of omeprazole and measurement of  
378 hydroxy omeprazole will allow approximation of CYP2C19 phenotype, and the sulphone  
379 metabolite will give CYP3A4 phenotype.

## 380 **6.5.2 Measuring activity of CYP2D6 by measuring the MR of dextromethorphan**

381 Dextromethorphan and its primary metabolites (CYP2D6- mediated dextrorphan; CYP3A4-  
382 mediated 3-methoxymorphinan) and secondary metabolite 3-hydroxymorphinan will be  
383 quantified in plasma using a modification of the original method from the Somogyi (CI)  
384 laboratory which originally used fluorescence detection (PMID 2305428) and which was  
385 easily able to identify CYP2D6 PMs (PMID 8841152) as the MR was over 1000-fold  
386 different between EMs and PMs. The primary modification being use of mass spectrometry  
387 instead of fluorescence, which will enhance sensitivity.

388

## 389 **6.5.3 Determining Phenotype of CYP2D6, CYP2C19 and CYP3A4 from the MR**

390 Phenotypic classification is based on the metabolite to parent drug metabolic ratio (MR). This  
391 is defined as the concentration of the metabolite divided by the concentration of the substrate  
392 according to a validated method using liquid chromatography tandem mass spectrometry  
393 quantification. The MR can then be used to give a representative phenotype (i.e., poor  
394 metaboliser (PM), intermediate metaboliser (IM), normal metaboliser (NM) or ultra-rapid  
395 metaboliser (UM).

396 Threshold levels for phenotype assessment have been detailed previously by Lenoir et al(13)  
397 (See Table 5). For noting in the Lenoir et al study CYP3A4 reference ranges for MR and SD  
398 were determined using midazolam as the probe medication.

399

	<b>PM</b> (Mean MR $\pm$ SD)	<b>IM</b> (Mean MR $\pm$ SD)	<b>NM</b> (Mean MR $\pm$ SD)	<b>UM</b> (Mean MR $\pm$ SD)
CYP2C19	0.18 $\pm$ 0.10	NA	0.76 $\pm$ 0.46	5.42 $\pm$ 2.46
CYP2D6	0.05 $\pm$ 0.02	0.46 $\pm$ 0.41	2.41 $\pm$ 1.79	NA
CYP3A4	0.22 $\pm$ 0.07	NA	0.57 $\pm$ 0.25	3.74 $\pm$ 1.50

400 Abbreviations: NA = Not applicable; MR = metabolic ration; SD = standard deviation.

401 **Table 5:** Threshold levels for phenotype assessments

402

## 403 **6.6 Methodology for Genotyping**



404 All participants will have genotyping performed for pharmaco-genes CYP3A4, CYP2C19  
 405 and CYP2D6 via either whole genome sequencing [WGS] (if patient has had previous WGS  
 406 or gene panel testing undertaken prior to PEGASUS enrolment) or genotyping via a targeted  
 407 gene panel looking at CYP3A4, CYP2C19 and CYP2D6 for patients who have not already  
 408 gene sequencing results available. This will involve either a blood sample being taken or  
 409 buccal swab. Some participants may have already consented to the MARVEL-PIC (HREC  
 410 89083) or PRECISION-ITS (PMCC HREC 101174) studies and thus will have the  
 411 genotyping result already available and reported within their EMR. These are existing  
 412 collaborations between A/Prof Conyers and Dr Marliese Alexander. Bloods will not be re-  
 413 taken if this result is already available, and the results already taken will be utilised for this  
 414 study.

415

## 416 7.0 PARTICIPANT TIMELINE

417 The study schema (Figure 1) and schedule of assessments (Table 6) provide an overview of  
 418 study visits and procedures.

419 **Table 6: Overview of Study Visits and Procedures**

PEGASUS	TRIAL PERIOD						
	Enrolment	Timepoints					Close-out
TIME POINT**	$-t_1$	$t_1$	$t_2$	$t_3$	$t_4$	$T_{5/6}$	$T_7$
<b>ENROLMENT:</b>							
Eligibility screen	X						
Informed consent	X						
Weight/height/vital signs	X						
Medical history, Clinical Examination and EMR review		X(a)	X(a)	X(a)	X(b)	X(b)	X(a)
<b>INTERVENTIONS :</b>							
Blood test: genotyping	X (C)						
Sub-therapeutic dosing omeprazole & dextromethorphan		X(d)	X(d)	X(d)	X(d)	X(d)	X(d)
Blood test: Phenotyping		X(e)	X(e)	X(e)	X(e)	X(e)	X(e)

<b>Blood test: CRP, PCT and cytokine panel</b>		X(f)				X(f)	X(f)
	<b>Acceptability Survey (TFA)</b>						X

420 **Timepoints:**  $t_1$  prior to enrolment,  $t_2$  at diagnosis,  $t_3$  at 2 months,  $t_4$  at 4 months,  $t_{5/6}$  at maximum of two febrile  
 421 episodes within a 4-month period,  $t_7$  at study conclusion.

- 422 a. Participant admitted to day oncology space, or if already an inpatient will be seen on the ward; will  
 423 then be administered dosing of dextromethorphan/omeprazole. Visit will take 2.5 hours.  
 424 b. Participant will be admitted to ward or day oncology fast track unit with febrile episode. Will then be  
 425 administered dosing of dextromethorphan/omeprazole. visit will take 2.5 hours.  
 426 c. If a participant is already enrolled on the “MARVEL-PIC” or “PRECISION” protocol, this test will  
 427 be omitted as results will already be available.  
 428 d. Medication will be dispensed as outlined in section 5.2 following medication reconciliation.  
 429 e. Bloods to measure enzyme activity following probe drug administration to be taken by central  
 430 venous access device and VAMS in consultation with the nursing team.  
 431 f. Inflammatory profile to be done on a maximum of two febrile admissions during the study period,  
 432 together with  $t_2$  and  $t_7$ .

433  
 434 **8.0 SAMPLE SIZE**

435 As the primary outcome is feasibility and acceptability a sample size estimate is not required,  
 436 however it should be noted that the investigators estimate that the recruitment period will be  
 437 either adequate to permit an assessment of feasibility and acceptability, or to determine that a  
 438 trial is not feasible due to low enrolment.

439  
 440 **9.0 RECRUITMENT**

441  
 442 **9.1 Achieving Sample Size**

443 This study is aiming to enrol 10 patients. To mitigate the risk of poor enrolment we will align  
 444 recruitment with routine hospital care and admissions to minimize burden to the patient.  
 445 Understanding acceptability of the trial is an important endpoint and, as such, we will try and  
 446 understand failure to recruit using short pre-scripted questions at the time of consent.

447  
 448 **9.2 Recruitment**

449 Clinical trial assistants or academic pharmacists at each centre will screen eligible patients  
 450 through the outpatient or inpatient department. The duration of the recruitment period is  
 451 estimated to be a 24-month interval depending on each centre’s recruiting rate. No financial  
 452 incentives will be provided to trial investigators or patients for enrolment in the recruitment  
 453 period.

454

455 **10. ALLOCATION**

456 **10.1 Sequence generation and Concealment**

457 This study is partially blinded and non randomised.

458

459 **10.2 Implementation**

460 Following consent, the research assistant or academic pharmacist enrolling the patient will

461 enter details onto the study database.

462

463 **10.3 Blinding**

464 The patients, pharmacists and physicians are unblinded to the pharmacogenomic results. The

465 scientific team assessing probe medication MR will be blinded to genotype.

466

467 **METHODS: DATA COLLECTION, MANAGEMENT, ANALYSIS**

468

469 **11.0 DATA COLLECTION PRIMARY OUTCOME AND SECONDARY OUTCOMES**

470

471 **11.1 Eligibility Screen**

472

473 The screening visit will take place once a new Hodgkin Lymphoma or Non-Hodgkin

474 Lymphoma diagnosis is made in an eligible patient.

475 Prior to any study specific procedures being performed, written informed consent will be

476 obtained from the patient/guardian(s). The screening visit will take place over 1 day or a

477 number of days depending on the patient/family schedule. The following assessment will be

478 undertaken at the screening visit.

479 

- Inclusion/exclusion criteria check

480 

- Written informed consent

481 

- Medical History including medication reconciliation.

482 

- Weight/height/vital signs

483 

- Review of EMR

484 

- Blood draw or buccal swab for genotyping of pharmacogenes (2mL – 5mL) in an

485 EDTA tube if WGS or panel PGx data not already available for patient on

486 MARVEL-PIC [National Randomised Controlled Trial PGx Implementation –

487 HREC 89083] or PRECISION [Peter MacCallum PGx study – HREC 101174]

488 studies. Absolute minimum required is 2mL for WGS.

489 **NOTE:** In the unlikely event that the PI of the study is on service at the RCH when there is a  
490 potential eligible patient, the PI will ask another liquid stream team member of the Children's  
491 Cancer Centre to take over care of the patient to avoid any conflict of interest. At the PIs  
492 study site all Hodgkin's patients are treated by the solid stream medical team leaving only  
493 non-Hodgkin's patients to potentially fall under the PIs primary care. This would happen  
494 prior to the patient/guardian(s) being approached for study consent.

495

496 **Timing of Assessment:** t<sub>1</sub> at enrolment.

497

498 **Administration of Assessment:** PI or Academic pharmacist and bloods taken by nursing or  
499 pathology staff (for peripheral or CVAD blood samples) and performed by trained Academic  
500 Pharmacist or RA (for VAMS samples).

501

## 502 **11.2 Phenotyping visits [Standard]**

503 Visit to be conducted by PI, delegated AI, or Academic pharmacist.

504

505 These include the following timepoints: t<sub>1</sub> prior to enrolment, t<sub>2</sub> at diagnosis, t<sub>3</sub> at 2 months, t<sub>4</sub>  
506 at 4 months and at t<sub>7</sub> at study conclusion.

507 Prior to a phenotyping assessment the following assessments will be undertaken:

- 508     ▪ Vital signs/weight/height
- 509     ▪ Review of medical history
- 510     ▪ Clinical Examination
- 511     ▪ Medication Reconciliation
- 512     ▪ Review of EMR

513 Following these assessments, the participant will be deemed suitable for probe drug  
514 administration and two hours later bloods for phenotyping via (i) central venous access  
515 device and (ii) VAMS.

516

### 517 ***Peripheral or Central Venous Access Device bloods***

518 Enzyme activity will be determined by taking 2mL – 5mL of blood (EDTA) 2 hours after  
519 administration of the probe drug. The patients unique study identifier will be attached to the  
520 blood tube along with the sampling timepoint. These will also be annotated within the  
521 *REDCap* database.

522 Immediately after the bloods are taken samples will be centrifuged at 2000g and samples will  
523 be transferred to polypropylene microtubes and stored at -20 degrees Celsius until MR  
524 analysis.

525

### 526 ***Volumetric Absorptive Microsampling (VAMS)***

527 This approach uses minute amounts of dried blood obtained via VAMS prior to LC-MS  
528 analysis. A VAMS device is used to sample 20µl of blood. The VAMS uses an innovative  
529 microsampling device, constituted by a hard plastic handle fitted with a detachable tip made  
530 of proprietary, porous polymeric material(14). The tip is capable of absorbing a field liquid  
531 sample volume according to its size and independently of sample density or viscosity. After  
532 absorption the specimen is left to dry and is then ready for storage(14). The patients unique  
533 study identifier will be attached to the VAMS along with the sampling timepoint. These will  
534 be annotated in the *REDCap* database. All samples will be stored at room temperature prior  
535 to batch processing for MR analysis.

536

537 **Timing of Assessment after probe drug:** Blood should be drawn as close as possible to 2  
538 hours after probe administration with an acceptable window of +/-30minutes. If for any  
539 reason blood draw does not occur in this window (1.5 to 2.5 hours after probe  
540 administration), blood draw should still be attempted up to 6 hours, with documented  
541 protocol deviation as delayed assessment. No blood draw should be attempted beyond 6  
542 hours after probe drug administration, with documented protocol deviation as missed  
543 assessment. For all blood draws accurate documentation of the time of probe drug  
544 administration and blood draw is imperative.

545

546 **Timing of Assessment after enrollment:**  $t_2$  at diagnosis,  $t_3$  at 2 months,  $t_4$  at 4 months,  $t_{5/6}$  at  
547 a maximum of two febrile episodes within 4-month period and at  $t_7$  at study conclusion  
548 (when finished treatment).

549

550 **Administration of Assessment:** PI or Academic pharmacist and bloods taken by nursing or  
551 pathology staff (for peripheral or CVAD blood samples) and performed by trained Academic  
552 Pharmacist or RA (for VAMS samples).

553

### 554 **11.3 Phenotyping visits [Febrile Illness]**

555 These study visits will occur without scheduling  $t_{5/6}$  at maximum of two inpatient febrile  
556 episodes within 4-month period of enrolment. The PI of the study, academic pharmacists, and  
557 research assistants as part of the research team will be notified of enrolled patients being  
558 admitted with febrile illnesses by collaborating physicians on the ward or the nurses within  
559 oncology fast track clinic.

560 Prior to a phenotyping assessment the following assessments will be undertaken:

- 561     ▪ Vital signs/weight/height
- 562     ▪ Review of medical history
- 563     ▪ Clinical Examination
- 564     ▪ Medication Reconciliation
- 565     ▪ Review of EMR

566 Following these assessments by a paediatric or adult oncologist and academic pharmacist  
567 within the team, a check will be undertaken with the treating medical team to gain consent for  
568 proceeding with dosing of probe medications. Once this is confirmed probe drug  
569 administration will occur and two hours later bloods for phenotyping (2mL – 5mL) via  
570 central venous access device.

571

572 **Timing of Assessment after probe drug:** Blood should be drawn as close as possible to 2  
573 hours after probe administration with an acceptable window of +/-30minutes. If for any  
574 reason blood draw does not occur in this window (1.5 to 2.5 hours after probe  
575 administration), blood draw should still be attempted up to 6 hours, with documented  
576 protocol deviation as delayed assessment. No blood draw should be attempted beyond 6  
577 hours after probe drug administration, with documented protocol deviation as missed  
578 assessment. For all blood draws accurate documentation of the time of probe drug  
579 administration and blood draw is imperative.

580

581 **Timing of Assessment after enrollment:**  $t_{5/6}$  at a maximum of two febrile episodes within a  
582 4-month period.

583

584 **Administration of Assessment:** PI or Academic pharmacist and bloods taken by nursing or  
585 pathology staff (for peripheral or CVAD blood samples) and performed by trained Academic  
586 Pharmacist or RA (for VAMS samples).

587

588

## 589 **11.4 Description of Procedures**

### 590 **11.4.1 Genotyping**

591 All participants will have genotyping performed for pharmaco-genes CYP3A4, CYP2C19  
592 and CYP2D6 via either WGS (if patient has had previous WGS or gene panel testing  
593 undertaken prior to PEGASUS enrolment) or genotyping via a targeted gene panel looking at  
594 CYP3A4, CYP2C19 and CYP2D6 for patients who have not already gene sequencing results  
595 available. This will involve either a blood sample being taken or buccal swab. Some  
596 participants may have already consented to the MARVEL-PIC (HREC 89083) or  
597 PRECISION (PMCC HREC 101174) studies and thus will have the genotyping result already  
598 available and reported within their EMR these are existing collaborations between A/Prof  
599 Conyers and Dr Marliese Alexander. Bloods will not be re-taken if this result is already  
600 available, and the results already taken will be utilised for this study.

601

602 Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics  
603 Working Group (DPWG) guidelines will be used to predict and classify the participant's  
604 phenotype based on individual genotype when this result is available.

605

606 **Timing of Assessment:** This is performed at enrolment ( $t_1$ ).

607

608 **Administration of Testing:** Testing ordered by PI/Academic pharmacist in the EMR and  
609 bloods taken by nursing or pathology staff (for peripheral or CVAD blood samples) and  
610 performed by trained Academic Pharmacist or RA (for VAMS samples).

611

### 612 **11.4.2 Probe Drug Administration and bloods for phenotyping**

613 Participants will receive probe drug administration as outlined in section 6.3.1. Two hours  
614 (+/- 30minutes) following probe drug administration bloods will be drawn from the  
615 participants central venous access device or via VAMS for phenotyping of CYP2C19,  
616 CYP3A4 and CYP2D6.

617 Volumetric absorptive micro sampling (VAMS) is a recently developed sample collection  
618 method that enables single-drop blood collection in a minimally invasive manner. Blood  
619 biomolecules can be extracted and processed for analysis via mass spectrometry.

620

621 **Timing of Assessment:**  $t_2$  at diagnosis,  $t_3$  at 2 months,  $t_4$  at 4 months,  $t_{5/6}$  at a maximum of  
622 two febrile episodes within a 4-month period and at  $t_7$  at study conclusion (when finished  
623 treatment).

624

625 **Administration of Testing:** Testing ordered by PI/Academic pharmacist and bloods taken by  
626 nursing or pathology staff (for peripheral or CVAD blood samples) and performed by trained  
627 Academic Pharmacist or RA (for VAMS samples).

628

### 629 **114.3 Inflammatory profiling**

630 Serum levels of PCT, CRP and cytokine analysis will be performed at baseline and at a  
631 maximum of 2 febrile episodes within a 4-month period. Concentrations of CRP will be  
632 measured from lithium heparin whole blood sample, directly after blood collection using  
633 latex enhanced immunoturbidimetry. Blood samples will be centrifuged at 2,000 g and 4°C  
634 for 10 minutes and serum samples stored at -80°C until analysis. A panel of 48 inflammatory  
635 cytokines will be measured using the Bio-RAD Bio-Plex Pro Human cytokine screening  
636 panel ([bio-rad.com/en-au](http://bio-rad.com/en-au)). This screening panel detects a comprehensive set of studied and  
637 biologically relevant cytokines including those shown to be predictive of severe infection in  
638 children with cancer and febrile neutropenia(15). This technique allows simultaneous  
639 analysis of multiple samples together using small sample volumes.

640

641 **Timing of Assessment:**  $t_2$  at diagnosis and  $t_{5/6}$  at a maximum of two febrile episodes within  
642 4-month period and at  $t_7$  at study conclusion.

643

644 **Administration of Testing:** Testing ordered by PI/Academic pharmacist and bloods taken by  
645 nursing or pathology staff.

646

### 647 **11.4.4 Review of Electronic Medical Record (EMR) and Medication Reconciliation**

648 The EMR will be reviewed to check end organ function at time of study visits (i.e., recent  
649 bloods for liver function tests, urea, electrolytes and creatinine and full blood count) to  
650 confirm ongoing eligibility and to complete a medication reconciliation.



651 Medication reconciliation will include details of regular medications, dose, administration  
652 method and frequency. These will be entered into the *REDCap* database. Of interest we will  
653 document if patients have ingested drugs known to potentially affect hepatic drug  
654 metabolism. Pharmacists will conduct a thorough check using resources recommended by  
655 Medicines Information Centres (i.e., Flockharts drug interactions table - [https://drug-  
656 interactions.medicines.iu.edu/MainTable.aspx](https://drug-interactions.medicines.iu.edu/MainTable.aspx)).

657

658 **Timing of Assessment:**  $t_2$  at diagnosis,  $t_3$  at 2 months,  $t_4$  at 4 months,  $t_{5/6}$  at a maximum of  
659 two febrile episodes within 4-month period and at  $t_7$  at study conclusion (when finished  
660 treatment).

661

662 **Administration of Testing:** Performed by Academic pharmacist.

663

#### 664 **11.4.5 Acceptability Survey**

665 We will apply the (TFA) to (i) explore reasons for decline in consent for participating in  
666 pharmacogenomic and phenoconversion testing; and (ii) explore associations between  
667 decliners' perceptions of acceptability and non-participation. The survey is provided in  
668 Supplemental Files 3-4.

669 **Eligibility:** Participant enrolled in PEGASUS.

670 **Timing of Assessment:** This is performed at  $t_7$  at study conclusion (when finished treatment).

671 **Duration:** 10 minutes

672 **Administration:** Survey will be disseminated via email through the *REDCap* database. The  
673 Academic pharmacist will ensure release date at the end of cancer treatment of the survey.

674

#### 675 **11.4.6 Structured Questions for Decline in Consent**

676 As described in 8.4.6 we will provide a short 5-minute survey for patients (Appendix 3) or  
677 parents/guardians (Appendix 4) at the time of decline of consent. The survey is provided in  
678 Supplemental Files 5-6.

679 **Eligibility:** Parent or carer of child who declined consent in PEGASUS.

680 **Timing:** At time of decline in consent

681 **Duration:** Less than 5 minutes

682 **Administration:** Structed interview; questions asked by study team at time of decline in  
683 consent.

684

685 If participants/guardians decline initial consent, verbal consent will be taken to answer the  
686 short decline consent survey. The study team will explain that a short decline to consent  
687 survey is not mandatory but in itself can help us to understand why the study is not  
688 acceptable to participants.

689

690 No participants/guardians details will be recorded as part of the decline in consent study.

691 They will be given a study identifier be marked as “declined to consent” and only the answers  
692 to the questions will be recorded in REDCap.

693

## 694 **12.0 RETENTION**

695

696 Retention in the study is aided by the academic pharmacist/PhD student conducting weekly  
697 quality assurance assessments on data collection. Patients are contacted to meet any  
698 outstanding endpoints [i.e. TFA]. All study participants are provided with the ability to  
699 discuss their pharmacogenomic result at the time they are available with a member of the  
700 study team. Weekly newsletters are provided via the hospital electronic mail system for  
701 awareness of the broader enrolling health care professional team.

702

## 703 **13.0 DATA MANAGEMENT**

704

### 705 **13.1 Data Forms and Data Entry**

706 PEGASUS Study results will be kept on a *REDCap* database. This is a secure database run by  
707 the Murdoch Children’s Research Institute. All paper files and consents will be kept locked  
708 away securely in a filing cabinet at each participating site.

709

710 Data will be collected in an identifiable manner. Upon entry of this data into *REDCap*,  
711 participants will be allocated a unique patient identifier. Consents and PGx reports will be  
712 uploaded to this database, in addition to key endpoint data collected as part of the study.

713 Information extracted from the database will be de-identified however delegated members of

714 the study team will have access to re-identify the study data for data entry and integrity  
715 purposes.

716

717 All database information is protected within Murdoch Children's Research Institute using the  
718 *REDCap* database by a triple encryption process between the remote user, the server and the  
719 *REDCap* database. No data can leave the database in an identifiable format. All data  
720 extraction will be de-identified for all users at all times, thus privacy and confidentiality will  
721 be maintained. The database itself is password protected and only researchers involved in the  
722 study will have the ability to access information collected.

723

724 We are required to keep information collected as part of this study for at least fifteen (15)  
725 years following the last publication of the study. Following that time, all information that was  
726 collected will be securely destroyed.

727

### 728 **13.2 Governance for Data Management and reporting**

729 The Principal Investigator (PI) is responsible for the design and conduct of the trial,  
730 preparation of protocol and revisions, preparation of case report forms (CRF) within  
731 REDCap, organising steering committee meetings, managing the clinical trials office,  
732 publishing study reports and membership of the trial management committee (TMC). The  
733 Steering Committee (SC) agrees on the final protocol, includes lead investigators from the  
734 two with responsibilities of recruitment of patients and liaising with the PI, reviewing study  
735 progress and if necessary, agreeing to changes of the protocol. TMC consists of the Principal  
736 Investigator and co-Investigator (MA) Academic Pharmacists (CM, EW, RD, DK) and PhD  
737 student. The team contribute to organisation of steering committee meetings, provide annual  
738 risk report to Human Research Ethics Committee (HREC) and Melbourne Clinical Trials  
739 Committee (MCTC), assess adverse events and serious unexpected adverse events (SUSAR)  
740 with appropriate reporting to HREC and MCTC. They are responsible for maintenance of the  
741 database, budget administration, HREC updates and amendments and randomisation.

### 742 **13.3 Data Endpoints and Databank Guidelines**

743 Data endpoints to be recorded in the PEGASUS study database are described in  
744 Supplemental File 7 with databank guidelines provided in Supplemental File 8.

745 **13.5 Data Quality Assurance**

746 An audit trail of transactions, available through the *REDCap database*, will be  
747 maintained to ensure data integrity and regulatory compliance. During data entry, each  
748 value entered will be subjected to a variety of quality control checks. Regular  
749 notifications identifying data quality issues and required follow-ups are regularly  
750 distributed by email to the national coordinator and then will be conveyed to the PI of the  
751 study. These data audits are discussed at weekly meetings with the pharmacogenomics  
752 study team.

753

754 **14 STATISTICS METHODS**

755

756 **14.1 Sample Size Estimation**

757

758 As the primary outcome is feasibility and acceptability a sample size estimate is not required,  
759 however it should be noted that the investigators estimate that the recruitment period will be  
760 either adequate to permit an assessment of feasibility and acceptability, or to determine that a  
761 trial is not feasible due to low enrolment.

762

763 **14.2 Population to be analysed**

764

765 The population analysed is Paediatric or AYA patient (6-25 years) with a new diagnosis of  
766 Lymphoma (Hodgkin or Non-Hodgkin subtype).

767

768 **14.3 Methods of analysis**

769 In this single arm study group comparisons are not planned and therefore inferential statistics  
770 will not be undertaken. Descriptive statistics of the proportions as described in outcomes will  
771 be reported as percentages with binomial logistic confidence intervals derived via exact  
772 method. Counts and continuous variables will be described with measures of central tendency  
773 (median or mean depending on normality) and variance (interquartile range or standard  
774 deviation). Incidence of genotype phenotype mismatch during the study will be described as  
775 events/treatment course.

776

## 777 **METHODS: MONITORING**

### 778 **15 DATA MONITORING**

#### 779 **15.1 Trial Monitoring Group [TMG]**

780 The PI is responsible for supervising any individual or party to whom they have delegated  
781 tasks at the study site. They must provide continuous supervision and documentation of their  
782 oversight. To meet this GCP requirement, a small group will be responsible for the day-to-  
783 day management of the study and will include at a minimum the PI, Academic Pharmacist  
784 and Research Assistant.

#### 785 **15.2 Pharmacogenomics Steering Committee (PSC)**

786 The Pharmacogenomics Steering Committee meet weekly to review the pharmacogenomic  
787 data for patients enrolled across the range of studies for MCRI pharmacogenomics team. This  
788 group consists of the Study PI Academic Pharmacist, Clinical Pharmacologist (as required)  
789 and a Bioinformatician, Paediatric Oncologist and co-PIs on this project. The meeting will  
790 serve the purpose of reviewing:

- 791     ▪ number of participants enrolled.
- 792     ▪ Schedule of upcoming assessments and assignment of Study team to undertake  
793         assessment.
- 794     ▪ Compliance with testing requirements.
- 795     ▪ Assess adverse events arising during the study.
- 796     ▪ Addressing Quality Audits from *REDCap* database.

#### 797 **15.3 Quality Control and Quality Assurance**

798 The Sponsor-Investigator will have responsibilities in relation to quality management. The  
799 Sponsor-Investigator has developed SOPs identify, evaluate quality assurance aspects of the  
800 study. The Sponsor-Investigator will also implement quality control (QC) procedures, which  
801 will include the data entry system and data QC checks. This will include internal quality  
802 management of study conduct, data and biological specimen collection, documentation and  
803 completion.

804

805

806

807 **16.0 HARMS**

808 An adverse event will be defined as any untoward medical occurrence in a subject without  
809 regard to the possibility of a causal relationship. For the purposes of this study AE will be  
810 those events occurring within 2 hours of (a) taking the probe drug dosing OR (b) having  
811 procedures performed (blood draws). Study safety monitoring will be coordinated by TMG  
812 chaired by the PI and the study research assistant. Reported adverse events, assessed and  
813 classified individually and in consultation, will be subject to clinical and scientific judgment  
814 as per the TMG. Full event definitions and reporting guidelines are detailed in Supplemental  
815 File 9.

816

817 **17.0 AUDITING**

818

819 Auditing is performed weekly. Auditing ensures compliance with % enrolment, release of  
820 pharmacogenomic report, % completion of surveys, % completion of all timepoints,  
821 admissions for febrile neutropenia and % completion of study endpoints. Reports of study  
822 progress are due yearly to the Ethics Committee of The Sydney Children's Hospital. The  
823 auditing is performed by an independent research assistant, separate to principal and associate  
824 investigators.

825 **18.0 ETHICS AND DISSEMINATION**

826 **18.1 RESEARCH ETHICS APPROVAL**

827 This protocol and the informed consent document and any subsequent amendments will be  
828 reviewed and approved by the Sydney Children's Hospital Human Research Ethics  
829 committee (HREC) prior to commencing the study. A letter of protocol approval by HREC  
830 will be obtained prior to the commencement of the study, as well as approval for other study  
831 documents requiring HREC review. This study was first approved by HREC in November  
832 2023 (Supplemental File 10).

833

834 A letter of authorisation will be obtained from the RGO prior to the commencement of the  
835 research at The Royal Children's Hospital. Institutional governance authorisation for any  
836 subsequent HREC-approved amendments will be obtained prior to implementation.

837

838 **18.2 PROTOCOL AMENDMENTS**

839 This study will be conducted in compliance with the current version of the protocol. Any  
840 change to the protocol document or patient information and consent form that affects the  
841 scientific intent, study design, participant safety, or may affect a participant's willingness to  
842 continue participation in the study is considered an amendment, and therefore will be written  
843 and filed as an amendment to this protocol and/or informed consent form. All such  
844 amendments will be submitted to the HREC, for approval prior to being implemented.

845

846 **18.3 CONSENT**

847

848 Consent will be undertaken using the approved participant or parent/guardian consent form  
849 (Supplemental File 11). Consent process for Patients and Parents/Guardians on study Patients  
850 and parents of patients will be informed of the study by the Study PI or Pharmacist assigned  
851 to this study (either at Peter MacCallum or The Royal Children's Hospital) following a  
852 screening of potentially eligible patients from the electronic medical record and weekly  
853 multi-disciplinary meetings with treating teams. Patients and their parents will be approached  
854 during routine outpatient appointments or, on the ward, if currently an inpatient. Patients and  
855 their parents will have the study explained to them and any questions will be answered. A  
856 screening of eligibility will be carried out and following this the parent will be left with a  
857 copy of the patient information and consent form (PICF).

858

859 In accordance with the National Statement, this study will utilise an active consent process.  
860 This will involve presenting potential participants with all the information they need to make  
861 an informed decision about participation. When the eligible participant or parent/guardian is  
862 invited to participate, they will be provided with detailed information on the purpose of the  
863 study, the extent of their involvement, the risks associated and the option to always refuse  
864 participation at any time will be explained.

865

866 The eligible participant or parent/guardian will be informed that enrolment into the study is a  
867 voluntary process and that the study is looking to map liver enzyme activities over time using  
868 sub-therapeutic administration of dextromethorphan and omeprazole across a maximum of 7  
869 timepoints over 4 months.

870

871 The approach to informed consent:

- 872     ▪ Participants and guardian(s) of participants will be informed of the study with an  
873     initial screening during their inpatient stay, or outpatient appointment, and left with a  
874     copy of the participant/parent PICF. This will be performed by the academic  
875     pharmacist, study research assistant or PI.
- 876     ▪ Prior to performing any trial-specific procedure (including screening procedures to  
877     determine eligibility), signed consent(s) form will be obtained for each participant.
- 878     ▪ The process will be that the investigator or delegated member of the trial team will  
879     discuss the study with relevant family members (i.e., parent/legal guardian).
- 880     ▪ Potential participants as well as enrolled participants will be able to contact the  
881     studies academic pharmacist or PI and have the ability to ask questions and request  
882     clarifications at any time prior to or during the study via email.
- 883     ▪ Where the patient is < 12 years of age, the parent/guardian will be provided with the  
884     parent/guardian PICF. The Parent/guardian will be asked to read and sign the study  
885     PICF if they agree and are willing for their child to participate.
- 886     ▪ Where the patient is >12 years of age the parent/guardian will be provided with the  
887     parent/guardian PICF, and the patient will be provided with the Adolescent/Young  
888     adult PICF. Both parents/guardians and patient will be asked to read and sign the  
889     respective PICFs if they agree and are willing to participate.

890

#### 891 **18.4 TREATMENT DISCONTINUATION, PARTICIPANT WITHDRAWALS AND** 892 **LOSSES TO FOLLOW-UP**

893 Participants and or their parent/legal guardian can withdraw consent for trial participation at  
894 any time during the trial.

895

896 Participants or legal guardians of participants can withdraw consent at any time of the study.  
897 This can be done by notifying the study PI (RCH: [rachel.conyers@mcri.edu.au](mailto:rachel.conyers@mcri.edu.au) and Peter  
898 Mac: [Marliese.Alexander@petermac.org](mailto:Marliese.Alexander@petermac.org)) or delegated member of the study team  
899 ([pharmaco.genomics@mcri.edu.au](mailto:pharmaco.genomics@mcri.edu.au)). This can be done via any means the participant, or their  
900 legal guardian feel most comfortable communicating the desire to withdraw from the study.



901

902 Participants may discontinue trial treatment for the following reasons.

903 Participant/legal guardian request to discontinue trial intervention for any reason including  
904 undisclosed reasons the investigator decides to discontinue a participant from the trial  
905 intervention if the participant.

906     ▪ Experiences a serious or intolerable adverse event such that continued trial  
907 intervention would not be in the best interest of the participant.

908     ▪ Develops during the trial period symptoms or conditions listed in the exclusion  
909 criteria.

910     ▪ Requires early discontinuation for another reason.

911

## 912 **18.5 STUDY CLOSURE**

913 A participant is considered to have completed the study if they have completed all phases of  
914 the study including the last visit or the last scheduled procedure shown in the schedule of  
915 assessments.

916 The end of the study is defined as completion of the last visit or procedure shown in the  
917 schedule of assessments by the last participant at all study sites. At this stage, the study PI  
918 will ensure that all HRECs and RGOs are informed.

919

### 920 **18.5.1 TEMPORARY HALT OR EARLY TERMINATION OF TRIAL**

921 If the trial is prematurely terminated or suspended, the PI will promptly inform trial  
922 participants, HREC and RGO, the funding and regulatory bodies, and provide the reason(s)  
923 for the termination or suspension. Circumstances that may warrant termination or suspension  
924 include, but are not limited to:

925     ▪ Determination of an unexpected, significant, or unacceptable risk to participants that  
926 meets the definition of a Significant Safety Issue (SSI).

927     ▪ Insufficient compliance to protocol requirements.

928     ▪ Data that is not sufficiently complete and/or evaluable.

929     ▪ Significant advantage confirmed by participation in the trial, such that the trial should  
930 close early.

931       ▪ In the case of concerns about safety, protocol compliance or data quality, the trial may  
932       resume once the concerns have been addressed to the satisfaction of the sponsor,  
933       HREC, RGO, funding and/or regulatory bodies.

934

935 The investigator may also withdraw all trial participants from the intervention if the trial is  
936 terminated. For the safety of all participants ceasing trial treatment in this event the protocol  
937 specified safety evaluations should be undertaken to capture new safety events and to assess  
938 unresolved safety events. All scheduled follow ups of trial participants should also occur  
939 following treatment discontinuation where possible.

940

#### 941 **18.5.2 LOSSES TO FOLLOW UP**

942 A participant will be considered lost to follow up if they fail to return for 2 scheduled visits  
943 and is unable to be contacted by trial staff. the following actions must be taken if a participant  
944 fails to the return to the clinic for a required trial visit.

- 945       ▪ The site study staff will attempt to contact the participant and reschedule the missed  
946       visit and counsel the participant on the importance of maintaining the assigned visit  
947       schedule and ascertain of the participant wishes to and or should continue in the trial.
- 948       ▪ Before a participant is deemed lost to follow-up the investigator or trial team will  
949       make every effort to regain contact with the participant (where possible, 3 telephone  
950       calls and if necessary, a certified email to the participant's last known email address  
951       recorded on *REDCap*. These contact attempts should be documented in the  
952       participants medical record or trial file.
- 953       ▪ Should the participant continue to be unreachable they will be considered to have  
954       withdrawn from the trial with a primary reason of lost to follow-up.

955

#### 956 **18.5.3 REPLACEMENT**

957 Participants who have been assigned a trial intervention will not be replaced.

958

959

960

961 **19.0 CONFIDENTIALITY**

962

963 Participant confidentiality is strictly held in trust by the PI, research staff, and the sponsoring  
964 institution MCRI and their agents. This confidentiality is extended to cover clinical  
965 information relating to participating participants.

966

967 The trial protocol, documentation, data and all other information generated will be held in  
968 strict confidence. No information concerning the trial, or the data will be released to any  
969 unauthorised third party, without prior written approval of the sponsoring institution.

970 Authorised representatives of the sponsoring institution may inspect all documents and  
971 records required to be maintained by the Investigator, including but not limited to, medical  
972 records (office, clinic or hospital) and pharmacy records for the participants in this trial. The  
973 Royal Children's Hospital and Peter MacCallum Cancer Institute will permit access to such  
974 records.

975

976 All evaluation forms, reports and other records that leave the site will be identified only by  
977 the Participant Identification Number (SID) to maintain participant confidentiality.

978 Clinical information will not be released without written permission of the participant, except  
979 as necessary for monitoring by HREC or regulatory agencies.

980

981 **20.0 PATIENT AND PUBLIC INVOLVEMENT**

982

983 Patients and public were first involved in the design of the research at the time of applying  
984 for the funding through the Medical Research Future Fund (MRFF). The protocol and grant  
985 application were developed with consumer participants from the Victorian Paediatric Cancer  
986 Consortium (VPCC) including consumer chief investigators on the grant application. Over  
987 the last 12 months we have had 4 separate meetings with the VPCC Patient Advisory Group  
988 to inform on pharmacogenomics study progress, attain feedback on project methodology and  
989 consent.

990

991

992

993

994 **21.0 DECLARATION OF INTEREST**

995

996 There are no identified financial or other competing interests for any investigators  
997 participating in this trial.

998

999 **22.0 ACCESS TO DATA**

1000

1001 The PI and steering committee will oversee the intra-study sharing process, at both the  
1002 interim analysis and at the end of the trial.

1003

1004 The scientist performing phenotyping analysis will be blinded to the genotyping results and  
1005 complete the analysis of the secondary endpoint blinded.

1006

1007 **23.0 DISSEMINATION POLICY**

1008

1009 **23.1 Trial Results**

1010

1011 At the conclusion of the trial, participants will be emailed the trial results to provide an  
1012 overview of the findings. MCRI holds the primary responsibility for publication of the results  
1013 of the trial.

1014 **Figure 1: Schema of PEGASUS Study Overview and Procedures.** Contraindication to probe  
1015 drug testing is assessed in consultation with paediatric oncologist in collaboration with  
1016 treating pharmacist. If patient misses a timepoint they automatically move to the next  
1017 timepoint in the study. Probe drug administration includes administration of  
1018 dextromethorphan and omeprazole as described in section 6.3.1 and 6.3.2 Phenotyping (MR)  
1019 measurements are performed 2 hours after probe drug administration. Febrile episodes up to a  
1020 maximum of two episodes will be included in the study.

1021 **AUTHOR STATEMENT**

1022 The principal investigator for PEGASUS is RC in collaboration with MA whose team  
1023 contributed to the writing of the study. RC, BF, TS, AG, MA and AS were involved in initial  
1024 drafting. AH designed the bioinformatic workflow and pharmacogenomics report for the  
1025 study. AS and CK designed laboratory assays for phenotyping. CM, DK, EW, RD, JS, AS,  
1026 CK have contributed to refinement and editing of the protocol. DE is laboratory head and has  
1027 had oversight to the trial rollout and design. All authors contributed to the protocol  
1028 development and/or edited and approved the final manuscript.

1029

1030 **FUNDING**

1031

1032 PEGASUS is funded through a nationally competitive Medical Research Future Fund Grant  
1033 (EPCDRI Paediatric Cancer MRF/2007620) as part of the Pharmacogenomics discovery aim.  
1034 This funding source had no role in the design of this study and will not have any role during  
1035 its execution, analyses, interpretation of the data, or decision to submit results.

1036

1037 **COMPETING INTEREST STATEMENT**

1038

1039 The authors have no competing interests to declare.

1040

1041 **ACKNOWLEDGEMENTS**

1042

1043 This study is endorsed by the Victorian Paediatric Cancer Consortium (VPCC). VPCC  
1044 facilitated consumer participation in pharmacogenomics discovery and barriers and enablers  
1045 to implementation. We thank all of those who have contributed to the study. RC is supported  
1046 by the Kids Cancer Project, The Royal Children's Hospital Foundation, Victorian Paediatric  
1047 Cancer Consortium, The Medical Research Future Fund and holds a Murdoch Children's  
1048 Research Institute (MCRI) Clinician Scientist Fellowship. MA is supported by an NHMRC  
1049 Investigator Grant (GNT1196211) and holds a Peter MacCallum Cancer Centre Research  
1050 Leader Fellowship (SSRL2023). D.A.E is a member of the Novo Nordisk Foundation Center  
1051 for Stem Cell Medicine which is supported by a Novo Nordisk Foundation grant number  
1052 NNF21CC0073729 and is supported by National Health and Medical Research Council of  
1053 Australia (D.A.E), Heart Foundation of Australia and The Medical Research Future Fund.

1054 MCRI is supported by the Victorian Government's Operational Infrastructure Support  
1055 Program.

1056

1057

## 1058 **20. REFERENCES**

- 1059 1. Helsby N, Yong M, Burns K, Findlay M, Porter D. Cyclophosphamide bioactivation  
1060 pharmacogenetics in breast cancer patients. *Cancer Chemother Pharmacol*. 2021;88(3):533-  
1061 42.
- 1062 2. Burns KE, Goldthorpe MA, Porteus F, Browett P, Helsby NA. CYP2C19 genotype-  
1063 phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-  
1064 metabolising activity. *Cancer Chemother Pharmacol*. 2014;73(3):651-5.
- 1065 3. Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern?  
1066 *Rheumatol Int*. 2012;32(9):2601-4.
- 1067 4. Frederique Rodieux YD, Victoria Rollason, Caroline F Samer, Kuntheavy Ing Lorenzini.  
1068 Practice of CYP450 genotyping and phenotyping in children in a real-life setting. *Frontiers*  
1069 *in Pharmacology*. 2023;14:11130100.
- 1070 5. Bosilkovska M, Samer CF, Deglon J, Rebsamen M, Staub C, Dayer P, et al. Geneva  
1071 cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood  
1072 spots. *Clin Pharmacol Ther*. 2014;96(3):349-59.
- 1073 6. Lloret-Linares C, Rollason V, Lorenzini KI, Samer C, Daali Y, Gex-Fabry M, et al.  
1074 Screening for genotypic and phenotypic variations in CYP450 activity in patients with  
1075 therapeutic problems in a psychiatric setting, a retrospective study. *Pharmacol Res*.  
1076 2017;118:104-10.
- 1077 7. Rollason V, Lloret-Linares C, Lorenzini KI, Daali Y, Gex-Fabry M, Piguet V, et al.  
1078 Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and  
1079 Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to  
1080 Analgesics: A Retrospective Study. *J Pers Med*. 2020;10(4).
- 1081 8. Ing Lorenzini K, Desmeules J, Rollason V, Bertin S, Besson M, Daali Y, et al. CYP450  
1082 Genotype-Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting.  
1083 *Front Pharmacol*. 2021;12:730637.
- 1084 9. Foulds JA, Maggo SD, Kennedy MA. Personalised prescribing in psychiatry: Has  
1085 pharmacogenomics delivered on its promise? *Aust N Z J Psychiatry*. 2016;50(6):509-10.
- 1086 10. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions  
1087 potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of  
1088 therapeutic drug monitoring. *Ther Drug Monit*. 2007;29(6):687-710.
- 1089 11. Bosilkovska M, Samer C, Deglon J, Thomas A, Walder B, Desmeules J, et al.  
1090 Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450  
1091 Phenotyping using Innovative Dried Blood Sampling Method. *Basic Clin Pharmacol Toxicol*.  
1092 2016;119(3):284-90.
- 1093 12. Kocur A, Pawinski T. Volumetric Absorptive Microsampling in Therapeutic Drug  
1094 Monitoring of Immunosuppressive Drugs-From Sampling and Analytical Issues to Clinical  
1095 Application. *Int J Mol Sci*. 2022;24(1).
- 1096 13. Lenoir C, Niederer A, Rollason V, Desmeules JA, Daali Y, Samer CF. Prediction of  
1097 cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions

- 1098 using physiologically based pharmacokinetics. CPT Pharmacometrics Syst Pharmacol.  
1099 2022;11(1):30-43.
- 1100 14. Mandrioli R, Mercolini L, Protti M. Blood and Plasma Volumetric Absorptive  
1101 Microsampling (VAMS) Coupled to LC-MS/MS for the Forensic Assessment of Cocaine  
1102 Consumption. Molecules. 2020;25(5).
- 1103 15. Doerflinger M, Haeusler GM, Li-Wai-Suen CSN, Clark JE, Slavin M, Babl FE, et al.  
1104 Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children  
1105 With Cancer and Febrile Neutropenia. Front Immunol. 2021;12:641879.  
1106



